Home > Research programmes > Biomedical informatics >

The Chemogenomics Laboratory was established in September 2003 with the incorporation of Dr. Jordi Mestres at the GRIB after a 7-year experience in pharmaceutical industry (1 year at Pharmacia&Upjohn in USA and 6 years at Organon in the Netherlands and UK). Today, apart from its head, the lab is composed of one post-doctoral researcher and 5 PhD students, with a current vacancy for a second post-doctoral researcher.
In terms of scientific production, within the period 2004-2007, the lab has published 17 articles in ISI journals and 2 book chapters. Research in the lab is done at the interface between chemistry, biology, and informatics, which requires a multidisciplinary team of skilled individuals in different fields. The ultimate aim is to develop and apply novel integrative biochemoinformatics tools for the systematic annotation of molecules to entire target families of therapeutic relevance. This information can then be used either upstream to identify chemical probes for target validation or downstream to identify novel hits for lead generation in the drug discovery process.
The Chemogenomics Lab has two main methodological research lines, namely, research on the Chemome and the research on the Proteome. In addition to these methodological lines, we have recently initiated four therapeutic research lines directed to the disease areas of cardiovascular, obesity, pain, and oncology. A brief description of each line is provided next:
Generating Chemical Graph Identifiers. Fast and robust algorithms for indexing molecules have been historically considered strategic tools for the management and storage of large chemical libraries. This lab has developed a modified and further extended version of the MEQNUM naming adaptation of the Morgan algorithm for the generation of a chemical graph identifier (CGI). This new version corrects for the collisions recognized in the original adaptation and includes the ability to deal with tautomerism, regioisomerism, optical isomerism, and geometrical isomerism.
Publications: (i) Garriga R, Gregori-Puigjané E, Mestres J. Indexing Molecules with Chemical Graph Identifiers. J Chem Inf Model (submitted)
Defining Biologically-relevant Molecular Descriptors. A novel set of molecular descriptors called SHED (SHannon Entropy Descriptors) has been developed. They are derived from distributions of atom-centered feature pairs extracted directly from the topology of molecules. Similarity between pairs of molecules is then assessed by calculating the Euclidean distance of their SHED profiles, under the assumption that molecules having similar pharmacological profiles should contain similar features distributed in a similar manner.
Publications: (i) Gregori-Puigjané E, Mestres J. SHED: Shannon Entropy Descriptors from Topological Feature Distributions. J Chem Inf Model 2006; 46:1615-22; (ii) Mestres J, Martín-Couce L, Gregori-Puigjané E, Cases M, Boyer S. Ligand-based Approach to In Silico Pharmacology: Nuclear Receptor Profiling. J Chem Inf Model 2006; 46:2725-36; (iii) Mestres J, Maggiora GM. Putting Molecular Similarity into Context: Asymmetric Indices for Field-based Similarity Measures. J Math Chem 2006; 39:107-18.
Constructing Virtual Chemical Spaces. The ability to generate novel synthetically-feasible biologically-active candidate molecules by computational means has long been pursued as a comprehensive and efficient approach to explore the vast chemical space potentially compatible to a given target space. We are developing a new ligand-based de novo design approach referred to as SHIFT, for Structural Hopping by Isosteric Fragment Transformations, and is based on the concept of a bioisosteric molecular shift defined as the exchange of a chemical structure for another of the same biological class.
Functional coverage of the proteome by structures. Tools and resources for translating the remarkable growth witnessed in recent years in the number of protein structures determined experimentally into actual gain in the functional coverage of the proteome are increasingly necessary. The Chemogenomics Lab has developed FCP, a publicly accessible continuously updated web tool dedicated to analyzing the current state and trends of the population of structures within protein families.
Publications: (i) Garcia-Serna R, Opatowski L, Mestres J. FCP: Functional Coverage of the Proteome by Structures. Bioinformatics 2006; 22:1792-3; (ii) Mestres J. Representativity of Target Families in the Protein Data Bank: Impact for Family-directed Structure-based Drug Discovery. Drug Discov Today 2005; 10:1629-37.
SuSe: Dictionary of protein surface segments. Based on the basic assumption that similar chemical functionalities should bind to similar protein environments we are constructing an integrative database connecting small molecule fragments to protein surface segments on the basis of structural information present in the Protein Data Bank.
Therapeutic Research Lines. References to individual protein targets and bioactive small molecules associated to multifactorial diseases can be found scattered in multiple bibliographic sources over the years. Mining these sources, we are collecting lists of targets associated to four therapeutic areas, namely, cardiovascular, obesity, pain, and oncology, and organising them using functional classification schemes in the four main protein families of therapeutic relevance, namely, enzymes, G protein-coupled receptors, ion channels, and nuclear receptors. Each disease-associated target space is then taken to interrogate an annotated chemical library and extract the bioactive chemical space connected to the corresponding target space. Some of these bioactive ligands were also found to have affinity for targets not directly linked to its respective diseases, thus constituting a valuable indirect source to infer the potential disease-associated off-target space. Compilation, classification, and integration of this prior knowledge provide a comprehensive perspective of the pharmacological space relevant to modern global drug discovery.
© IMIM Institut Municipal d'Investigació Mèdica 2008 - Legal Note - Accessibility